» Articles » PMID: 26991123

MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Non-Small Cell Lung Cancer

Overview
Journal PLoS One
Date 2016 Mar 19
PMID 26991123
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Severe radiation-induced toxicities limit treatment efficacy and compromise outcomes of lung cancer. We aimed to identify microRNA-related genetic variations as biomarkers for the prediction of radiotherapy-induced acute toxicities. We genotyped 233 SNPs (161 in microRNA binding site and 72 in processing gene) and analyzed their associations with pneumonitis and esophagitis in 167 stage III NSCLC patients received definitive radiation therapy. Sixteen and 11 SNPs were associated with esophagitis and pneumonitis, respectively. After multiple comparison correction, RPS6KB2:rs10274, SMO:rs1061280, SMO:rs1061285 remained significantly associated with esophagitis, while processing gene DGCR8:rs720014, DGCR8:rs3757, DGCR8:rs1633445 remained significantly associated with pneumonitis. Patients with the AA genotype of RPS6KB2:rs10274 had an 81% reduced risk of developing esophagitis (OR: 0.19, 95% CI: 0.07-0.51, p = 0.001, q = 0.06). Patients with the AG+GG genotype of SMO:rs1061280 had an 81% reduced risk of developing esophagitis (OR: 0.19, 95% CI: 0.07-0.53, p = 0.001, q = 0.06). Patients with the GG+GA genotype of DGCR8:rs720014 had a 3.54-fold increased risk of pneumonitis (OR: 3.54, 95% CI: 1.65-7.61, p <0.05, q <0.1). Significantly cumulative effects of the top SNPs were observed for both toxicities (P-trend <0.001). Using bioinformatics tools, we found that the genotype of rs10274 was associated with altered expression of the RPS6KB2 gene. Gene-based analysis showed DGCR8 (p = 0.010) and GEMIN4 (p = 0.039) were the top genes associated with the risk of developing pneumonitis. Our results provide strong evidence that microRNA-related genetic variations contribute to the development of radiotherapy-induced acute esophagitis and pneumonitis and could thus serve as biomarkers to help accurately predict radiotherapy-induced toxicity in NSCLC patients.

Citing Articles

MicroRNAs targeted mTOR as therapeutic agents to improve radiotherapy outcome.

Taeb S, Rostamzadeh D, Amini S, Rahmati M, Eftekhari M, Safari A Cancer Cell Int. 2024; 24(1):233.

PMID: 38965615 PMC: 11229485. DOI: 10.1186/s12935-024-03420-3.


Examination of eQTL Polymorphisms Associated with Increased Risk of Progressive Complicated Sarcoidosis in European and African Descent Subjects.

Casanova N, Camp S, Gonzalez-Garay M, Batai K, Garman L, Montgomery C Eur J Respir Med. 2024; 5(1):359-371.

PMID: 38390497 PMC: 10883688.


Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer.

Yan W, Hu H, Tang B Onco Targets Ther. 2019; 12:8015-8022.

PMID: 31686857 PMC: 6777428. DOI: 10.2147/OTT.S203550.


Genetic polymorphism in DGCR8 is associated with late onset of preeclampsia.

Huang X, Li Z, Lei J, Wang D, Zhang Y BMC Med Genet. 2019; 20(1):151.

PMID: 31484500 PMC: 6727569. DOI: 10.1186/s12881-019-0887-7.


Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy.

Pang Y, Hou X, Yang C, Liu Y, Jiang G Mol Cancer. 2018; 17(1):91.

PMID: 29769134 PMC: 5956614. DOI: 10.1186/s12943-018-0840-y.


References
1.
Jacob N, Cooley J, Yee T, Jacob J, Alder H, Wickramasinghe P . Identification of sensitive serum microRNA biomarkers for radiation biodosimetry. PLoS One. 2013; 8(2):e57603. PMC: 3581493. DOI: 10.1371/journal.pone.0057603. View

2.
Grundberg E, Small K, Hedman A, Nica A, Buil A, Keildson S . Mapping cis- and trans-regulatory effects across multiple tissues in twins. Nat Genet. 2012; 44(10):1084-9. PMC: 3784328. DOI: 10.1038/ng.2394. View

3.
Uyterlinde W, Belderbos J, Baas C, van Werkhoven E, Knegjens J, Baas P . Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin. Clin Lung Cancer. 2013; 14(5):541-8. DOI: 10.1016/j.cllc.2013.04.001. View

4.
Li J, Lindstrom L, Foo J, Rafiq S, Schmidt M, Pharoah P . 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nat Commun. 2014; 5:4051. PMC: 4082638. DOI: 10.1038/ncomms5051. View

5.
Sridharan S, Basu A . S6 kinase 2 promotes breast cancer cell survival via Akt. Cancer Res. 2011; 71(7):2590-9. PMC: 3070841. DOI: 10.1158/0008-5472.CAN-10-3253. View